Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: Identification of pronounced redox activity and characterization of their antitumor activity

Journal of Medicinal Chemistry

Volumn 53, Issue 15, 2010, Pages 5759-5769

  Jansson, Patric J ^a   Sharpe, Philip C ^b   Bernhardt, Paul V ^b   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 ACETYLPYRIDINE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; COPPER COMPLEX; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; OXIDATION REDUCTION POTENTIAL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHELATING AGENTS; COORDINATION COMPLEXES; COPPER; DRUG SCREENING ASSAYS, ANTITUMOR; GLUTATHIONE; GLUTATHIONE DISULFIDE; HUMANS; LIGANDS; OXIDATION-REDUCTION; PYRIDINES; REACTIVE OXYGEN SPECIES; STRUCTURE-ACTIVITY RELATIONSHIP; THIOSEMICARBAZONES;

EID: 77955365279     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100561b     Document Type: Article

References (58)

1. Bernhardt, P. V.; Caldwell, L. M.; Chaston, T. B.; Chin, P.; Richardson, D. R. Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues J. Biol. Inorg. Chem. 2003, 8, 866-880
2. Richardson, D. R.; Sharpe, P. C.; Lovejoy, D. B.; Senaratne, D.; Kalinowski, D. S.; Islam, M.; Bernhardt, P. V. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity J. Med. Chem. 2006, 49, 6510-6521
3. Buss, J. L.; Greene, B. T.; Turner, J.; Torti, F. M.; Torti, S. V. Iron chelators in cancer chemotherapy Curr. Top. Med. Chem. 2004, 4, 1623-1635
4. Kalinowski, D. S.; Richardson, D. R. Future of toxicology-iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy Chem. Res.Toxicol. 2007, 20, 715-720
5. Rakba, N.; Loyer, P.; Gilot, D.; Delcros, J. G.; Glaise, D.; Baret, P.; Pierre, J. L.; Brissot, P.; Lescoat, G. Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines Carcinogenesis 2000, 21, 943-951
6. Torti, S. V.; Torti, F. M.; Whitman, S. P.; Brechbiel, M. W.; Park, G.; Planalp, R. P. Tumor cell cytotoxicity of a novel metal chelator Blood 1998, 92, 1384-1389
7. Yu, Y.; Kalinowski, D. S.; Kovacevic, Z.; Siafakas, A. R.; Jansson, P. J.; Stefani, C.; Lovejoy, D. B.; Sharpe, P. C.; Bernhardt, P. V.; Richardson, D. R. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors J. Med. Chem. 2009, 52, 5271-5294
8. Kalinowski, D. S.; Richardson, D. R. The evolution of iron chelators for the treatment of iron overload disease and cancer Pharmacol. Rev. 2005, 57, 547-583
9. Trinder, D.; Zak, O.; Aisen, P. Transferrin receptor-independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression Hepatology 1996, 23, 1512-1520
10. Richardson, D. R.; Baker, E. The uptake of iron and transferrin by the human malignant melanoma cell Biochim. Biophys. Acta 1990, 1053, 1-12
11. Richardson, D.; Baker, E. Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate J. Biol. Chem. 1992, 267, 13972-13979
12. Yu, Y.; Wong, J.; Lovejoy, D. B.; Kalinowski, D. S.; Richardson, D. R. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond Clin. Cancer Res. 2006, 12, 6876-6883
13. Morgan, E. H. Transferrin biochemistry, physiology and clinical significance Mol. Aspects Med. 1981, 1-123
14. Larrick, J. W.; Cresswell, P. Modulation of cell surface iron transferrin receptors by cellular density and state of activation J. Supramol. Struct. 1979, 11, 579-586
15. Daniel, K. G.; Gupta, P.; Harbach, R. H.; Guida, W. C.; Dou, Q. P. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells Biochem. Pharmacol. 2004, 67, 1139-1151
16. Gupte, A.; Mumper, R. J. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment Cancer Treat. Rev. 2009, 35, 32-46
17. Xie, H.; Kang, Y. J. Role of copper in angiogenesis and its medicinal implications Curr. Med. Chem. 2009, 16, 1304-1314
18. Hassouneh, B.; Islam, M.; Nagel, T.; Pan, Q.; Merajver, S. D.; Teknos, T. N. Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer Mol. Cancer Ther. 2007, 6, 1039-1045
19. Yuan, J.; Lovejoy, D. B.; Richardson, D. R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment Blood 2004, 104, 1450-1458
20. Lowndes, S. A.; Adams, A.; Timms, A.; Fisher, N.; Smythe, J.; Watt, S. M.; Joel, S.; Donate, F.; Hayward, C.; Reich, S.; Middleton, M.; Mazar, A.; Harris, A. L. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors Clin. Cancer Res. 2008, 14, 7526-7534
21. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D. R. A class of iron chelators with a wide spectrum of potent anti-tumor activity that overcome resistance to chemotherapeutics Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 14901-14906
22. Kalinowski, D. S.; Yu, Y.; Sharpe, P. C.; Islam, M.; Liao, Y. T.; Lovejoy, D. B.; Kumar, N.; Bernhardt, P. V.; Richardson, D. R. Design, synthesis, and characterization of novel iron chelators: structure?activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents J. Med. Chem. 2007, 50, 3716-3729
23. Richardson, D. R.; Kalinowski, D. S.; Richardson, V.; Sharpe, P. C.; Lovejoy, D. B.; Islam, M.; Bernhardt, P. V. 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity J. Med. Chem. 2009, 52, 1459-1470
24. Liu, Z. D.; Hider, R. C. Design of iron chelators with therapeutic application Coord. Chem. Rev. 2002, 232, 151-171
25. Barnham, K. J.; Masters, C. L.; Bush, A. I. Neurodegenerative diseases and oxidative stress Nat. Rev. Drug Discovery 2004, 3, 205-214
26. Marzano, C.; Pellei, M.; Tisato, F.; Santini, C. Copper complexes as anticancer agents Anti-Cancer Agents Med. Chem. 2009, 9, 185-211
27. Paterson, B. M.; Karas, J. A.; Scanlon, D. B.; White, J. M.; Donnelly, P. S. Versatile new bis(thiosemicarbazone) bifunctional chelators: synthesis, conjugation to bombesin(7?14)-NH2, and copper-64 radiolabeling Inorg. Chem. 2010, 49, 1884-1893
28. Xiao, Z.; Donnelly, P. S.; Zimmermann, M.; Wedd, A. G. Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. Insights into mechanisms of copper uptake and hypoxia selectivity Inorg. Chem. 2008, 47, 4338-4347
29. Bernhardt, P. V.; Sharpe, P. C.; Islam, M.; Lovejoy, D. B.; Kalinowski, D. S.; Richardson, D. R. Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity J. Med. Chem. 2009, 52, 407-415
30. Kalinowski, D. S.; Sharpe, P. C.; Bernhardt, P. V.; Richardson, D. R. Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure?activity relationships of novel thiohydrazone analogues J. Med. Chem. 2007, 50, 6212-6225
31. Hathaway, B. J. A new look at the stereochemistry and electronic properties of complexes of the copper(II) ion Struct. Bonding (Berlin) 1984, 57, 55-118
32. Halcrow, M. A. Interpreting and controlling the structures of six-coordinate copper(II) centres. When is a compression really a compression? Dalton Trans. 2003, 4375-4384
33. Huettermann, J.; Kappl, R. EPR and ENDOR of metalloproteins: copper and iron Electron Paramagn. Reson. 2004, 19, 116-173
34. Valko, M.; Morris, H.; Cronin, M. T. Metals, toxicity and oxidative stress Curr. Med. Chem. 2005, 12, 1161-1208
35. Fenton, H. J. H. On a new reaction of tartaric acid Chem. News 1876, 33, 190
36. Halliwell, B.; Gutteridge, J. M. Biologically relevant metal ion-dependent hydroxyl radical generation. An update FEBS Lett. 1992, 307, 108-112
37. Wardman, P.; Candeias, L. P. Fenton chemistry: an introduction Radiat. Res. 1996, 145, 523-531
38. Pisoni, R. L.; Acker, T. L.; Lisowski, K. M.; Lemons, R. M.; Thoene, J. G. A cysteine-specific lysosomal transport system provides a major route for the delivery of thiol to human fibroblast lysosomes: possible role in supporting lysosomal proteolysis J. Cell Biol. 1990, 110, 327-335
39. Myhre, O.; Andersen, J. M.; Aarnes, H.; Fonnum, F. Evaluation of the probes 2?,7?-dichlorofluorescin diacetate, luminol, and lucigenin as indicators of reactive species formation Biochem. Pharmacol. 2003, 65, 1575-1582
40. Blair, D.; Diehl, H. Bathophenanthrolinedisulphonic acid and bathocuproinedisulphonic acid, water soluble reagents for iron and copper Talanta 1961, 163-174
41. Santos, N. C.; Figueira-Coelho, J.; Martins-Silva, J.; Saldanha, C. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects Biochem. Pharmacol. 2003, 65, 1035-1041
42. Meister, A.; Anderson, M. E. Glutathione Annu. Rev. Biochem. 1983, 52, 711-760
43. Liang, S. X.; Richardson, D. R. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1 Carcinogenesis 2003, 24, 1601-1614
44. Yu, Y.; Kovacevic, Z.; Richardson, D. R. Tuning cell cycle regulation with an iron key Cell Cycle 2007, 6, 1982-1994
45. Zhao, R.; Planalp, R. P.; Ma, R.; Greene, B. T.; Jones, B. T.; Brechbiel, M. W.; Torti, F. M.; Torti, S. V. Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator Biochem. Pharmacol. 2004, 67, 1677-1688
46. Richardson, D. R. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process Biochim. Biophys. Acta 1997, 1320, 45-57
47. Noulsri, E.; Richardson, D. R.; Lerdwana, S.; Fucharoen, S.; Yamagishi, T.; Kalinowski, D. S.; Pattanapanyasat, K. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells Am. J. Hematol. 2009, 84, 170-176
48. Kowol, C. R.; Berger, R.; Eichinger, R.; Roller, A.; Jakupec, M. A.; Schmidt, P. P.; Arion, V. B.; Keppler, B. K. Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase J. Med. Chem. 2007, 50, 1254-1265
49. Kowol, C. R.; Eichinger, R.; Jakupec, M. A.; Galanski, M.; Arion, V. B.; Keppler, B. K. Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N, N -dimethyl(chalcogen) semicarbazones J. Inorg. Biochem. 2007, 101, 1946-1957
50. Martinelli, R. A.; Hanson, G. R.; Thompson, J. S.; Holmquist, B.; Pilbrow, J. R.; Auld, D. S.; Vallee, B. L. Characterization of the inhibitor complexes of cobalt carboxypeptidase A by electron paramagnetic resonance spectroscopy Biochemistry 1989, 28, 2251-2258
51. Sheldrick, G. M. SHELX97. Programs for Crystal Structure Analysis, release 97-2; University of Göttingen: Göttingen, Germany, 1998.
52. Farrugia, L. J. ORTEP-3 for Windows: A version of ORTEP-III with a graphical user interface (GUI) J. Appl. Crystallogr. 1997, 30, 565
53. Richardson, D. R.; Tran, E. H.; Ponka, P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents Blood 1995, 86, 4295-4306
54. Richardson, D. R.; Ponka, P. The iron metabolism of the human neuroblastoma cell. Lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis J. Lab. Clin. Med. 1994, 124, 660-671
55. Mladenka, P.; Kalinowski, D. S.; Haskova, P.; Bobrovova, Z.; Hrdina, R.; Simunek, T.; Nachtigal, P.; Semecky, V.; Vavrova, J.; Holeckova, M.; Palicka, V.; Mazurova, Y.; Jansson, P. J.; Richardson, D. R. The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity Chem. Res. Toxicol. 2009, 22, 208-217
56. Meister, A. Glutathione metabolism and its selective modification J. Biol. Chem. 1988, 263, 17205-17208
57. Griffith, O. W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine Anal. Biochem. 1980, 106, 207-212
58. Griffith, O. W.; Meister, A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n -butyl homocysteine sulfoximine) J. Biol. Chem. 1979, 254, 7558-7560